Skip to main content

Table 1 Characteristics of the discovery and the validation cohorts

From: A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy

 

C3 (discovery, n = 864)

C5 (validation, n = 242)

Characteristic

n

%

n

%

Sex

 Male

579

67.0

165

68.2

 Female

285

33.0

77

31.8

T

 1

476

55.1

124

51.2

 2

122

14.1

21

8.7

 3

251

29.1

92

38

 4

13

1.5

4

1.7

 NA

2

0.2

1

0.4

N

 0

322

37.3

173

71.5

 1/2

46

5.3

26

10.7

 X

495

57.3

40

16.5

 NA

1

0.1

3

1.2

M

 0

537

62.2

170

70.2

 1

82

9.5

38

15.7

 X

209

24.2

33

13.6

 NA

36

4.2

1

0.4

Histology

 ccRCC

512

59.3

134

55.4

 pRCC

287

33.2

86

35.5

 chRCC

65

7.5

16

6.6

 mixed

0

0.0

6

2.5

Overall survival

 Alive

648

75.0

161

66.5

 Deceased

216

25.0

81

33.5

CSS

 Censored

714

82.6

188

77.7

 Events

135

15.6

54

22.3

 NA

15

1.7

0

0.0

Follow-up, years

 Median

3.0

4.8

 Range

0 to 16.2

0 to 21.2

 NA

2

0.2

0

0.0

Age, years

 Median

60

64

 Range

17 to 90

25 to 90

 NA

3

0.3

0

0.0

Tumor size, cm

 Median

5.1

5.8

 Range

1 to 25

1.3 to 17.7

 NA

105

12.2

2

0.8

  1. NA Not available, CSS Cancer-specific survival